Chargement en cours...
Predicting Response to Vedolizumab in Inflammatory Bowel Disease
Vedolizumab is known to be safe, well-tolerated, and effective. However, as personalization becomes an increasingly important aspect of IBD care and in lieu of guidelines to inform clinicians on positioning of biologics, there is a need to reliably predict response to inform patient preferences and...
Enregistré dans:
| Publié dans: | Front Med (Lausanne) |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7145386/ https://ncbi.nlm.nih.gov/pubmed/32300596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2020.00076 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|